Charles River Laboratories International, Inc. (CRL)
CRLNYSEBiotechnology: Commercial Physical & Biological Resarch
$352.04
-1.07 (-0.30%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $352.78 -0.16%
- Market cap
- $16.90bn
- P/E
- 33.3
- EPS, last 4 quarters
- $10.56
- Dividend yield
- –
- Day range
- –
- 52-week range
- $146.20 to $379.63
- Average volume
- 349.0k
- Previous close
- $353.11
Analysts
14 coveringBuy13 buy, 1 hold, 0 sell
Targets a year out average $350.23, -0.5% from here
Earnings
next estimate $3.26Next report
Dec 2025
+2.6%
Mar 2026
+5.1%
Jun 2026
+11.0%
Sep 2026
+3.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $994.23m | $995.83m | $1.00bn | $982.73m |
| Gross profit | $309.68m | $294.66m | $363.37m | $357.87m |
| Operating income | -$283.44m | $119.90m | $119.89m | $202.64m |
| Net income | -$276.56m | -$14.84m | -$1.48m | $333.07m |
Last four quarters: revenue $3.98bn, margin 1.0%, free cash flow $399.63m
News
8 latest- Here's Why Charles River Laboratories (CRL) is a Strong Momentum StockZacks · 1 day ago
- Charles River Laboratories to Acquire Frontage’s Bioanalysis and DMPK BusinessesFintel · 1 day ago
- Unlocking Charles River (CRL) International Revenues: Trends, Surprises, and ProspectsZacks · 1 day ago
- Charles River To Buy Frontage's Bioanalysis And DMPK Operations For Up To $545 Mln Cash RTTNews · 1 day ago
- Charles River Laboratories International Q3 Earnings Call HighlightsMarketBeat · 5 days ago
- Charles River (CRL) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- Charles River Laboratories Announces Third-Quarter 2026 ResultsFintel · 6 days ago
- Charles River Q3 Earnings & Revenues Top Estimates, Stock RisesZacks · 6 days ago
The company
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- Region
- North America
- Website
- criver.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.